Pain Points: Drug-Drug Interactions and Opioid Therapy in Pain Management
Coadministration of drugs should be done with caution, because drug-drug interactions can cause serious adverse effects. Being cognizant of relevant pharmacodynamics, pharmacokinetics, and pharmacogenetics aspects of a variety of drugs, including analgesics, can reduce such effects.
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA).
- Discuss the importance of drug-drug interactions in opioid therapy
- Focus on metabolic pathways to explain the potential high risk of drug-drug interactions with opioids and other drugs
Oscar A. de Leon-Casasola, MD
Professor of Anesthesiology and Medicine
The Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
Chief, Pain Medicine and Professor of Oncology
Roswell Park Cancer Institute
The following relevant financial relationships have been disclosed by faculty:
Oscar A. De Leon-Casasola, MD: Advisory Board for Adapt Pharma Inc.; Esteve Pharma; Medtronic; and Stimgenics.
Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email [email protected] or call (877) 477-4633.
AMA PRA Category 1 Credits™
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.
Pri-Med Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Pri-Med Institute and Miller Medical Communications, LLC. Pri-Med Institute is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 040308.
This program has been approved for 0.28 contact hour of continuing education, which includes 0.28 hour of pharmacology.
Instructions for Obtaining Credit
Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 2 out of the 3 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen.
For PAs, the NCCPA accepts for Category 1 CME credit activities designated for AMA PRA Category 1 Credit™.
MOC Credit Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 0.25 MOC
- 0.25 AMA PRA Category 1 Credit™
This course is offered through Pri-Med. To take this course you will be redirected to Pri-Med's website. You must have an account with Pri-Med in order to complete this activity.
Mocingbird continues to work with our CME partner network to provide courses directly to you. We appreciate your patience as we work toward that goal!